Epigenetic Therapy in Human Choriocarcinoma

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Noriyuki, Narahara, Hisashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837331/
https://www.ncbi.nlm.nih.gov/pubmed/24281181
http://dx.doi.org/10.3390/cancers2031683
_version_ 1782292425289498624
author Takai, Noriyuki
Narahara, Hisashi
author_facet Takai, Noriyuki
Narahara, Hisashi
author_sort Takai, Noriyuki
collection PubMed
description Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies.
format Online
Article
Text
id pubmed-3837331
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38373312013-11-22 Epigenetic Therapy in Human Choriocarcinoma Takai, Noriyuki Narahara, Hisashi Cancers (Basel) Review Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies. MDPI 2010-09-10 /pmc/articles/PMC3837331/ /pubmed/24281181 http://dx.doi.org/10.3390/cancers2031683 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Takai, Noriyuki
Narahara, Hisashi
Epigenetic Therapy in Human Choriocarcinoma
title Epigenetic Therapy in Human Choriocarcinoma
title_full Epigenetic Therapy in Human Choriocarcinoma
title_fullStr Epigenetic Therapy in Human Choriocarcinoma
title_full_unstemmed Epigenetic Therapy in Human Choriocarcinoma
title_short Epigenetic Therapy in Human Choriocarcinoma
title_sort epigenetic therapy in human choriocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837331/
https://www.ncbi.nlm.nih.gov/pubmed/24281181
http://dx.doi.org/10.3390/cancers2031683
work_keys_str_mv AT takainoriyuki epigenetictherapyinhumanchoriocarcinoma
AT naraharahisashi epigenetictherapyinhumanchoriocarcinoma

Ejemplares similares